Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma von Tuscano, Joseph M., Dutia, Mrinal, Chee, Karen, Brunson, Ann, Reed‐Pease, Christine, Abedi, Mehrdad, Welborn, Jeanna, O'Donnell, Robert T.

Volltext

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐ H odgkin lymphoma von Tuscano, Joseph M., Dutia, Mrinal, Chee, Karen, Brunson, Ann, Reed‐Pease, Christine, Abedi, Mehrdad, Welborn, Jeanna, O'Donnell, Robert T.

Volltext

Lenalidomide Overcomes FcγRIIIa-Mediated Resistance to Rituximab In Patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL): A Correlative Analysis of a Phase 2 Stu... von Dutia, Mrinal, DeRoock, Ian, Reed-Pease, Christine, Tuscano, Joseph

Volltext

R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL) von Dutia, Mrinal, DeRoock, Ian, Chee, Karen, O'donnell, Robert, Quirch, Christine, Reed-Pease, Christine, Tuscano, Joseph

Volltext